EMA pharmacovigilance committee initiates first EU-wide drug safety review
This article was originally published in Scrip
The European Medicines Agency's newly formed pharmacovigilance committee has begun its first EU-wide drug safety review by looking to address concerns with codeine-containing medicines used for post-operative pain relief in children.
You may also be interested in...
An independent audit of the new EU Clinical Trials Information System has finally commenced, indicating that plans are on track for the EU Clinical Trial Regulation to be implemented from December 2021.
EU regulators have agreed on supplementary pharmacovigilance requirements applicable to COVID-19 vaccines following approval.
The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.